Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) Stock Price Down 2.9% – What’s Next?

Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) was down 2.9% during mid-day trading on Tuesday . The stock traded as low as $5.02 and last traded at $5.05. Approximately 21,899 shares were traded during trading, a decline of 95% from the average daily volume of 460,126 shares. The stock had previously closed at $5.20.

Wall Street Analyst Weigh In

Separately, HC Wainwright raised their price target on shares of Neuphoria Therapeutics Inc. – Common Stock from $8.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, February 4th.

Neuphoria Therapeutics Inc. – Common Stock Stock Down 2.9 %

The business has a 50 day moving average of $5.16.

Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) last released its quarterly earnings data on Friday, February 14th. The company reported ($1.23) EPS for the quarter, beating the consensus estimate of ($2.01) by $0.78. The firm had revenue of $660 billion for the quarter. Equities research analysts predict that Neuphoria Therapeutics Inc. – Common Stock will post -1.56 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Cyndeo Wealth Partners LLC acquired a new position in shares of Neuphoria Therapeutics Inc. – Common Stock during the first quarter valued at about $58,000. Jane Street Group LLC bought a new position in Neuphoria Therapeutics Inc. – Common Stock in the 4th quarter valued at about $46,000. Finally, Lynx1 Capital Management LP acquired a new position in Neuphoria Therapeutics Inc. – Common Stock during the 4th quarter valued at about $157,000. Institutional investors and hedge funds own 15.90% of the company’s stock.

About Neuphoria Therapeutics Inc. – Common Stock

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor.